UK Moratorium on Use of Genetic Tests by Insurers Extended
By Philippa Brice,
PHG Foundation
| 01. 21. 2015
Untitled Document
The UK Government and Association of British Insurers (ABI) have agreed to extend their voluntary moratorium on the use of predictive genetic test results by insurers by another two years, to 2019.
Originally established in 2001 and periodically reviewed and renewed ever since, the Concordat and Moratorium on Genetics and Insurance is a voluntary agreement intended to protect the interests of both individuals (by ensuring appropriate access to insurance) and of insurers (by ensuring access to information about risks).
Once again, there has been no significant change to the substance of the agreement; individuals must only disclose genetic test results to insurers in the case of Huntington’s disease tests and for life insurance policies worth in excess of £500,000. It is worth noting that anyone undertaking a genetic test for Huntington’s disease almost certainly does so in the face of a family history of the condition, which must be disclosed to insurers anyway.
However, the concordat contains two new elements. An additional Annex 2 explains the important distinction between predictive and diagnostic genetic tests. Predictive or presymptomatic...
Related Articles
By Josie Ensor, The Times | 12.09.2025
A fertility start-up that promises to screen embryos to give would-be parents their “best baby” has come under fire for a “misuse of science”.
Nucleus Genomics describes its mission as “IVF for genetic optimisation”, offering advanced embryo testing that allows...
By Hannah Devlin, The Guardian | 12.06.2025
Couples undergoing IVF in the UK are exploiting an apparent legal loophole to rank their embryos based on genetic predictions of IQ, height and health, the Guardian has learned.
The controversial screening technique, which scores embryos based on their DNA...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...
By Vardit Ravitsky, The Hastings Center | 12.04.2025
Embryo testing is advancing fast—but how far is too far? How and where do we draw the line between preventing disease and selecting for “desirable” traits? What are the ethical implications for parents, children, clinicians, and society at large? These...
